RE: Company House29 Feb 2020 14:38
London, UK, 6 January 2020: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, announces that it has raised £200,000 of gross proceeds through the issue of 200,000,000 new ordinary shares at a price of 0.10 pence ("Issue price") per share ("Placing") with new and existing investors and the appointment of ETX Capital Limited ("ETX Capital") as joint broker to the Company with immediate effect.
ok they needed 200k to finish the drug testing the companies only worth 1million (at present) so for someone to buy into that you will have to dilute the shares they where selling at
it was going to be 0.1 p per share we are at 0.065p now this is crazy
do you actually have a plan?